INTERVIEW: Sativa Group ‘A Big Boost’ from Health Secretary’s Statement

Sativa Group (NEX: SATI) CEO Geremy Thomas joins DirectorsTalk to comment on the statement made by Health Secretary Matt Hancock. Geremy also explains the significance of appointing new broker Cenkos.

Sativa is a seed to Consumer medicinal cannabis and cannabidiol (CBD) wellness business, focused on the smart-sourcing of the raw material, advanced extraction, manufacture, testing, distribution, and research & development of medicinal cannabis and CBD products. The Company has a Home Office licence application in process which, when granted as the Directors believe it will be as the application is in its final stages, will enable the Company to engage in the highly regulated process of growing, strictly for medicinal research & development purposes only, Tetrahydrocannabinol (THC) rich cannabis flowers at its high-security Somerset headquarters.

The Company joined the UK’s NEX market in March 2018 as the UK’s first medicinal cannabis investment vehicle and since then has capitalised on its first-mover advantage, developing a substantial UK bridgehead into what the Company believes will be a significant market in the future. Two UK operating subsidiaries, PhytoVista Laboratories and George Botanicals, are already well established and fully trading with healthy gross margins in independent CBD testing and CBD wholesale & retail respectively.

Phytovista has conducted over 1000 independent tests and George Botanicals develops, manufactures and distributes low-THC CBD wellness products. Other important future revenue streams are at various stages of development from concept to actual launch, with the first Goodbody CBD wellness centre opening in Bath on 28th June.

Prior to the Listing, Sativa’s founder and CEO, Geremy Thomas, spent 12 months researching the global medical cannabis and CBD industries at his own personal expense. He based himself in Canada, the most advanced country in terms of medicinal cannabis acceptance and regulation, travelling to America, Australia, the Far East, and Europe to connect with industry leaders and participants. The Company on Listing was therefore already internationally connected, and this has given it a head start within the UK industry for smart-sourcing and the adoption of advanced value-add techniques and models.

In May 2019 the Company obtained permission from NEX Exchange to reclassify itself as a trading company, having delivered on its original investment strategy. Benefits of this include widening the appeal of the equity opportunity to additional types of investors including institutions and family offices, many of which are precluded from investing in fund-type vehicles.

Sativa has a highly experienced Medical Advisory Board, Chaired by Sir Alasdair Breckenridge, a former Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA). He is joined by Dr Matthew Brown, an award-winning pain consultant at The Royal Marsden Hospital, Dr. Peter Fedlshreiber, a barrister and physician specialising in medical law, and Dr. Stuart Ungar, co-founder of the Doctors Laboratory and who researched biochemical neuropsychopharmacology at the Royal Free Hospital.

The Company has a strong senior management team and Board team including Joseph Colliver FCA as Chief Financial Officer and a Board Director, and Jonathan Wearing, a seasoned City corporate financier, as Chairman. Dr Nick Horniman, Director of Regulatory Affairs, has over thirty years of experience in the veterinary industry and he co-ordinates the Group’s ongoing relationships with regulators such as the Home Office, Food Standards Agency (FSA) and the Veterinary Medicines Directorate (VMD). He is also investigating the significant opportunities for medicinal cannabis and CBD products in the pet and equine markets. Chris Jones, a retail management professional who was instrumental in building the Phones 4U chain, leads the team developing the Goodbody wellness centres, which will offer customers a variety of high-quality CBD products.

Sativa’s smart-sourcing strategy enables it to define the crucial factors of seed strain, growing techniques and environment, along with extraction methods, all of which are imperative to the quality of the end-product. Phytovista Laboratories confirms the cannabinoid profile and quality of each batch on delivery to ensure that it is regulatorily compliant, is free of unwanted chemical elements, and is of proven origin. The commercial off-take agreements that the Company is entering in to will contribute to quality assurance, forecasted forward quantities of supply, consistency, and pre-determined pricing, rather than spot pricing.

The Group’s activities include the Sativa Foundation, which awards research grants to academic institutions in order to further research & development into the efficacy of the full spectrum of cannabinoids. In April 2019 the Company entered into a three-year research agreement with King’s College London to research the impact of cannabinoids on inflammation and respiratory diseases.

Sativa has invested in two Canadian-based businesses, pharmaceutical company Veritas Pharma Inc. and a Rapid Dose Therapeutics Inc. Both of these provide Sativa with valuable know-how alongside their investment potential. The Company also has a 60% share of a joint venture with Germany’s Lexamed GmbH, providing a foothold into the German market.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn

    More articles like this

    DirectorsTalk

    CBD as a novel food: the UK’s stance post-Brexit

    The UK FSA’s announcements that it will consider novel food applications for CBD products stands in contrast to the position taken by the European Commission during the summer of 2020, who have currently ‘paused’ novel food

    DirectorsTalk

    What cannabinoids are found in CBD oils?

    CBD oils can be purely made from seeds or they can be a combination of cannabinoids, flavonoids, and terpenes. Every CBD oil is a little bit different, and you will want to make sure you read

    DirectorsTalk

    How the UK CBD industry is thriving in uncertain times

    This year covid-19 has hit hard with far-reaching economic implications for countries around the world. The United Kingdom is no exception as the economy has taken the brunt of the pandemic’s negative effects. However certain markets

    DirectorsTalk

    UK CBD market on a high

    Just when you thought the ‘hype’ around CBD adoption was a passing fad, UK’s nascent CBD market happens to be among the few industries maintaining an upward growth amidst the recent COVID-19 pandemic devastation in the

    DirectorsTalk

    How to integrate CBD oil into your diet

    The internet is awash with information and testimonies on the benefits of CBD oil and the potential that it has in alleviating a number of ailments. Whether or not some of these claims are true is

    DirectorsTalk

    Why should you choose CBD oil?

    Cannabidiol (CBD) is a non-psychoactive yet active chemical component among cannabinoids, a group of compounds found in marijuana plants otherwise known as Cannabis sativa. Conversely, Tetrahydrocannabinol (THC) is the principal psychoactive component that causes an intoxicating

    DirectorsTalk

    A guide to CBD

    What is CBD? CBD – It’s a relatively new product, but how can it benefit you? Most people haven’t even heard of it and yet it’s starting to appear in conversations around sports, food and beauty

    Sativa Group

    Is CBD oil legal in the UK?

    The legal status of CBD in the UK is reflected in many countries worldwide, with the main difference being the levels of THC allowed in the finished product. CBD has seen such a rapid rise to

    Sativa Group

    Sativa Group joins the ACI toxicology study

    As part of the Sativa Group PLC (AQUIS:SATI) ongoing commitment to continually deliver the highest level of regulatory compliance and substantiate ‘CBD you can trust’, the Company has become a member of the Association for the

    Sativa Group

    A comprehensive guide to CBD in the UK

    CBD is being added to products across the retail spectrum from food to make-up. According to claims by the Centre for Medical Cannabis, six million people in the UK have tried CBD, and this year the

    Sativa Group

    A new cannabis wellness era: A history of CBD

    Cannabis Sativa L. has been utilised for a large variety of ailments, industrial applications, and ceremonial uses for millennia. Evidence gathered from significant ancient sites has revealed that the plant was important, and even sacred, in

    Sativa Group

    How CBD can help level up your workout

    With gyms closed and group classes relegated to the online world, at-home workouts are the new normal. Feeling a bit lackluster after months of squats in your living room? Want a new solution so you can

    Sativa Group

    What is CBD? How does it work?

    What is CBD? It’s in everything from beauty products to lattes, but those three letters are thrown around so much that you’d be forgiven for not knowing what CBD is, exactly. More importantly, you might be wondering, is CBD safe?

    Sativa Group

    Sativa Group CSE conditionally approves Sativa Wellness Group

    Sativa Group plc (AQUIS:SATI) has announced that the Canadian Securities Exchange conditionally approved the Listing Application for Sativa Wellness Group Inc. on September 7, combining the operations of Sativa Group PLC and Stillcanna Inc. As previously